Several large retrospective cohort studies have reported a significantly lower incidence of urolithiasis in SGLT-2i users compared to patients treated with other hypoglycemics such as GLP-1 agonists or DPP-4i [6–8]. This evidence concerns the gene GCG and urolithiasis.